One Nucleus Genesis Digital 2020 – Key takeaways from our cell and gene therapy panel session
par Adrian Toutoungi
8+2+1 plus what? How UK data and market exclusivity rights will be affected from 1 January 2021
par Alison Dennis et Dr Paul England
Biologics and biosimilars litigation update
par Matthew Royle, Ph.D. et Dr. Nora E. Wessendorf, LL.M. (Washington)
SPC for ezetimibe/simvastatin considered invalid in preliminary relief proceedings
Targeted treatments – Part 3: the power of orphan drug protection
par Dr Paul England
German Federal Court of Justice invalidates Truvada SPC
Targeted treatments – Part 1: Targeted treatments: patents for particular populations
par Dr Paul England
Adrian Toutoungi, Josef Fuss and Matt Caskie discuss how biotech has managed its finances during the pandemic
par Adrian Toutoungi et Josef Fuss
Biologics and biosimilars litigation update
Conférences et Webinars
Retrouvez les analyses de nos experts sur les dernières questions juridiques.
Voir tous les évènements
One Nucleus Genesis Digital 2020 – Key takeaways from our cell and gene therapy panel session
par Adrian Toutoungi
8+2+1 plus what? How UK data and market exclusivity rights will be affected from 1 January 2021
par Alison Dennis et Dr Paul England
Biologics and biosimilars litigation update
par Matthew Royle, Ph.D. et Dr. Nora E. Wessendorf, LL.M. (Washington)
SPC for ezetimibe/simvastatin considered invalid in preliminary relief proceedings
Targeted treatments – Part 3: the power of orphan drug protection
par Dr Paul England
German Federal Court of Justice invalidates Truvada SPC
Targeted treatments – Part 1: Targeted treatments: patents for particular populations
par Dr Paul England
Adrian Toutoungi, Josef Fuss and Matt Caskie discuss how biotech has managed its finances during the pandemic
par Adrian Toutoungi et Josef Fuss
Biologics and biosimilars litigation update